Free Trial
NASDAQ:PDSB

PDS Biotechnology (PDSB) Stock Price, News & Analysis

PDS Biotechnology logo
$1.25 +0.01 (+0.81%)
As of 09:48 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About PDS Biotechnology Stock (NASDAQ:PDSB)

Key Stats

Today's Range
$1.23
$1.26
50-Day Range
$1.07
$1.62
52-Week Range
$0.85
$4.29
Volume
11,727 shs
Average Volume
549,911 shs
Market Capitalization
$58.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
Consensus Rating
Buy

Company Overview

PDS Biotechnology Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
38th Percentile Overall Score

PDSB MarketRank™: 

PDS Biotechnology scored higher than 38% of companies evaluated by MarketBeat, and ranked 737th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    PDS Biotechnology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    PDS Biotechnology has only been the subject of 1 research reports in the past 90 days.

  • Read more about PDS Biotechnology's stock forecast and price target.
  • Earnings Growth

    Earnings for PDS Biotechnology are expected to decrease in the coming year, from ($1.20) to ($1.35) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of PDS Biotechnology is -1.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of PDS Biotechnology is -1.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    PDS Biotechnology has a P/B Ratio of 3.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about PDS Biotechnology's valuation and earnings.
  • Percentage of Shares Shorted

    5.47% of the float of PDS Biotechnology has been sold short.
  • Short Interest Ratio / Days to Cover

    PDS Biotechnology has a short interest ratio ("days to cover") of 4.
  • Change versus previous month

    Short interest in PDS Biotechnology has recently decreased by 6.97%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    PDS Biotechnology does not currently pay a dividend.

  • Dividend Growth

    PDS Biotechnology does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.47% of the float of PDS Biotechnology has been sold short.
  • Short Interest Ratio / Days to Cover

    PDS Biotechnology has a short interest ratio ("days to cover") of 4.
  • Change versus previous month

    Short interest in PDS Biotechnology has recently decreased by 6.97%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    PDS Biotechnology has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for PDS Biotechnology this week, compared to 2 articles on an average week.
  • Search Interest

    4 people have searched for PDSB on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added PDS Biotechnology to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, PDS Biotechnology insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 9.20% of the stock of PDS Biotechnology is held by insiders.

  • Percentage Held by Institutions

    Only 26.84% of the stock of PDS Biotechnology is held by institutions.

  • Read more about PDS Biotechnology's insider trading history.
Receive PDSB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PDS Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PDSB Stock News Headlines

Overnight moves = possibly bigger returns
Here’s a chart everyone should see that dates back to 1993… As you can see, the top line shows the much bigger average market return from trading overnight… Versus the bottom line, which shows the more modest average return from trading during the day. Look at that gigantic difference! So if you prefer nice big overnight returns instead, I agree with you. That’s why I’ve designed a breakthrough trade to tap into that overnight trading frenzy. You can check that out right here. Obviously, I won’t make any reckless guarantees in the stock market, but… That eye-opening chart above is just the beginning of the benefits you’ll see to trading overnight. PLUS, you’ll also see what my #1 ranked asset is in the entire market… And what my “hands-off” stocks are that I wouldn’t touch with a 100-foot pole.tc pixel
See More Headlines

PDSB Stock Analysis - Frequently Asked Questions

PDS Biotechnology's stock was trading at $1.63 at the beginning of the year. Since then, PDSB stock has decreased by 23.3% and is now trading at $1.25.

PDS Biotechnology Corporation (NASDAQ:PDSB) announced its earnings results on Wednesday, August, 13th. The company reported ($0.21) earnings per share for the quarter, topping analysts' consensus estimates of ($0.24) by $0.03.
Read the conference call transcript
.

PDS Biotechnology's top institutional investors include Armistice Capital LLC (4.89%), Geode Capital Management LLC (0.91%), Jane Street Group LLC (0.15%) and Marshall Wace LLP (0.15%).
View institutional ownership trends
.

Shares of PDSB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that PDS Biotechnology investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Adobe (ADBE), Broadcom (AVGO) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
8/13/2025
Today
8/29/2025
Next Earnings (Estimated)
11/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PDSB
CIK
1472091
Employees
20
Year Founded
N/A

Price Target and Rating

High Price Target
$13.00
Low Price Target
$7.00
Potential Upside/Downside
+700.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.92)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$37.61 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-184.56%
Return on Assets
-79.00%

Debt

Debt-to-Equity Ratio
0.81
Current Ratio
2.92
Quick Ratio
2.92

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.34 per share
Price / Book
3.68

Miscellaneous

Outstanding Shares
46,633,000
Free Float
42,343,000
Market Cap
$58.29 million
Optionable
Optionable
Beta
0.95

Social Links

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:PDSB) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners